GLOBAL PANDEMIC PREVENTION & BIODEFENSE CENTER

A moon shot partnership between the public and private sectors, academia, and nonprofits to ensure a global pandemic never again brings the world to the brink.



The time to invest is now.

What is urgently needed is one cross-sector entity with the scale, resources, and talent to ensure the initiatives of all pandemic prevention stakeholders are coordinated to deliver maximum impact. Additionally, we need one body that can help accelerate the production and stockpiling of life-saving therapeutics and diagnostics, while improving surveillance and monitoring capabilities to help prevent and contain future outbreaks.

With a keen understanding of the challenges hampering current preparedness efforts, Connected DMV has a vision to create the world's only comprehensive center to coordinate a global pandemic prevention and response program. Called the Global Pandemic Prevention & Biodefense Center, this Center aims to harness all of the rich talent and critical health research, biotech, defense, and government assets that the world has to offer to deliver a full-scale response. The National Capital Region is uniquely positioned to be the host location for this herculean task because it is home to:

- 70 federal labs
- 800 life sciences companies
- Government agencies: FDA, NIH/NIAID, ASPR/BARDA, DARPA
- Seat of policy and political power
- 175 worldwide embassies and diplomatic missions

The flagship lead initiative of the Center will be AHEAD100. This ambitious, medical countermeasures program aims to develop and stockpile monoclonal antibodies (mAbs) for the world's top 100 pathogens across 25 pathogen families most likely to cause pandemics. The availability of this stockpile fills the critical time gap between outbreaks and activated vaccines during which a pandemic can be wholly avoided.

BUSINESS MODEL

501(c)(3) organization with co-equal participation across industry, government, academia, and philanthropy.

GOVERNANCE

Independent governance via a steering committee comprised of leaders across relevant domains. Following the Strategy Phase, a formal Board of Trustees will be installed. The steering committee and board will comprise public, private, academic, and community leaders.

KEY PARTICIPANTS

Dr. James Crowe, Dr. Richard Tubb, Dr. Steve Projan, Dr. Sachiko Kuno, Honorable Andy Weber, Connected DMV, The Bill & Melinda Gates Foundation, Bipartisan Commission on Biodefense, State of Maryland, Montgomery County, University System of Maryland, BioHealth Innovation, Maryland Technology Council, DLA Piper, and Biotech and Pharma industry leaders.

Global loss of life from COVID-19 exceeds 2.8 million people with economic loss estimated at over $10 trillion. Establishing the Center and preparing antibody solutions through Phase 1 trials will cost $2.5 billion and enable society to be weeks from a solution when an outbreak occurs saving countless lives and evading massive economic and societal disruption.

Further, the Center:

- Integrates across public, private, academia, and community participants
- Will be in proximity with NIH/NIAID, the FDA, DoD, ASPR/BARDA and others
- To be funded 50/50 by philanthropic and government monies
- Accelerates development/availability of monoclonal antibodies for world's top 100 pathogens
- Places a priority on traditionally underrepresented communities and populations
- Integrates with organizations such as the Bipartisan Commission on Biodefense
- Integrates with local government and community pandemic preparedness plans

TIMELINE

The Strategy Phase began in January 2021 and will be followed by a formal launch of the Center. AHEAD100 will begin upon confirmation of funding.

FUNDING MODEL & BUDGET

$2.5B to launch the Center and its lead initiative (AHEAD100) to be co-funded by the U.S. government, global coalitions, and philanthropy.

USE OF FUNDS

Costs to establish and staff the Center including payroll, technology, legal, and administrative support. The bulk of funds would go to a phased execution of the AHEAD100 program.

ECOSYSTEM

The ecosystem will comprise organizations and institutions from: Federal, State, and Local Government, Nonprofits, Industry, Academia, Health Care, Biotech, Defense, and Pharma.

STEERING COMMITTEE

Dr. James Crowe, Founder & Chief Scientist, AHEAD100
Stu Solomon, Co-Lead
Rich Bendis, Co-Lead

Non-Profits / NGOs		Academia	Government		Industry	
Biotechnology Innovation Organization (BIO) *Phyllis Arthur*	**Bipartisan Commission on Biodefense** *Dr. Asha George*	**University System of Maryland** *Dr. Jay Perman*	**NIH / NIAID / VRC** *Dr. John Mascola (ex-officio)*	**State of Maryland** *Secretary Kelly Schulz*	**Moderna** *Dr. Obadiah Plante*	**DLA Piper** *Hon. Jim Greenwood*
Brigadier Gen (ret.) White House Physician Emeritus *Dr. Richard Tubb*	**Former ASD for Nuclear, Chemical, and Biological Defense** *Hon. Andy Weber*	**Vanderbilt University Medical Center** *Dr. Jeff Balser*	**NIH / NIAID / MID** *Dr. Cristina Cassetti (ex-officio)*	**Montgomery County** *Hon. Marc Elrich*	**AstraZeneca** *Dr. Mark Esser*	**Founder, BeatTheReaper** *Dr. Steve Projan*
CEPI *Dr. Nick Jackson*	**World Health Organization (WHO)** *Dr. Soumya Swaminathan (ex-officio)*	**Consortium of Universities of Washington Metro Area** *Dr. Andrew Flagel*	**NIH / NCATS** *Dr. Mike Kurilla (ex-officio)*	**HHS / ASPR / BARDA** *Dr. Christopher Houchens (ex-officio)*	**Regeneron** *Dr. Christos Kyratsous*	**Twist Bioscience** *Dr. Emily Leproust*
Bill & Melinda Gates Foundation *Dr. Jenni Weisman*	**S&R Foundation** *Dr. Sachiko Kuno*	**Founder, AHEAD100** *Dr. James Crowe*	**Walter Reed Army Institute of Research** *Dr. Kayvon Modjarrad (ex-officio)*	**HHS / ASPR / BARDA** *Dr. Kimberly Armstrong (ex-officio)*	**Emergent BioSolutions** *Dr. Laura Saward*	**Berkeley Lights** *Dr. Keith Breinlinger*
US Pharmacopeia *Anthony Lakavage, JD*	**BioHealth Innovation** *Rich Bendis*	**Boston University** *Dr. Nahid Bhadelia*	**FDA** *Future*	**CDC** *Future*	**GSK** *Dr. Rebecca Farkas*	**Kaiser Permanente** *Ruth Williams-Brinkley*
Virginia Bio *John Newby*	**Maryland Tech Council** *Marty Rosendale*	**Wellcome Leap** *Dr. Duccio Medini*	**USAMRDC / USAMRIID** *Future*	**USAID** *Future*	**Becton Dickinson** *Dave Hickey*	**Various Biotech Companies** *Ken Kelley*
Montgomery County Economic Dev. Corp. *Ben Wu*	**Battelle National Biodefense Institute** *Dr. George Korch*	**Connected DMV** *Stu Solomon*	**JPEO-CBRND** *Future*		**eMed** Dr. Patrice Harris *(Prior AMA Chair)*	**Pinkston** Jim Traficant

GLOBAL PANDEMIC PREVENTION & BIODEFENSE CENTER
powered by CONNECTED DMV

INVESTING IN A WORLD WHERE A PANDEMIC NEVER HAPPENS AGAIN.



FY21: $25M

FY22: $350M

FY23-26: $2.2B

SECURING CURRENT FEDERAL FUNDING, INCLUDING ARPA, TO:

- Establish the Global Pandemic Prevention and Biodefense Center ("Center")
- Launch AHEAD100

SECURING FUTURE FEDERAL FUNDING TO:

- Build-out operations of the Center
- Begin mAbs development for 15 high priority pathogens
- Catalyze manufacturing and delivery innovation
- Drive capability demonstrations & coordinate training efforts

DELIVERING THE FULL OPERATIONS OF THE CENTER & A FULL SUITE OF MABS FOR ALL FUTURE RISK PATHOGENS:

- These funds will continue to drive:
  - Development of about 25 mAbs per year, at cost of $20M / mAbs
  - Innovation in terms of manufacturing process and dosage delivery
- Our goal is to raise funding through a co-funded model from the U.S. government, global coalitions, and philanthropy

WITH YOUR HELP, WE CAN DELIVER:

Growth of promising, innovative pandemic solutions (e.g., mAbs)

Driving enabling policies in support of future pandemic prevention

Durable cross-sector collaboration to enable prevention and rapid response

Immediate containment of future outbreaks